In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biogen Idec, Vernalis ally in Parkinson's disease; terminated

Executive Summary

Drug development company Vernalis PLC (focuses on neuroscience and oncology) licensed Biogen Idec (therapeutics for disorders in oncology, neurology, dermatology, and rheumatology) exclusive worldwide rights to develop and commercialize its lead compound V2006 (formerly VR 2006), an adenosine A2A receptor antagonist in Phase I for Parkinson's disease (PD).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies